Jefferies Group LLC Reiterates “Hold” Rating for Gilead Sciences, Inc. (GILD)
Jefferies Group LLC reissued their hold rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note released on Thursday. They currently have a $83.00 price target on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently weighed in on the stock. Vetr raised shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $74.58 target price on the stock in a research note on Tuesday, April 18th. J P Morgan Chase & Co reaffirmed an overweight rating and issued a $82.00 target price on shares of Gilead Sciences in a research note on Thursday, April 6th. Zacks Investment Research raised shares of Gilead Sciences from a hold rating to a buy rating and set a $76.00 target price on the stock in a research note on Tuesday, May 2nd. Barclays PLC reaffirmed an overweight rating and issued a $85.00 target price (down from $90.00) on shares of Gilead Sciences in a research note on Sunday, April 23rd. Finally, BidaskClub raised shares of Gilead Sciences from a strong sell rating to a sell rating in a research note on Thursday, June 22nd. Twelve equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of Buy and an average target price of $80.31.
Shares of Gilead Sciences (NASDAQ GILD) traded up 0.20% during midday trading on Thursday, hitting $76.09. 7,932,083 shares of the company traded hands. The stock has a market capitalization of $99.37 billion, a PE ratio of 8.26 and a beta of 1.20. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $82.10. The stock has a 50 day moving average of $69.98 and a 200-day moving average of $68.63.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the prior year, the firm posted $3.08 earnings per share. The company’s revenue for the quarter was down 8.2% on a year-over-year basis. Equities analysts forecast that Gilead Sciences will post $8.72 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.73%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.
In other news, Director John Francis Cogan sold 9,943 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total transaction of $668,666.75. Following the sale, the director now owns 47,562 shares in the company, valued at approximately $3,198,544.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 40,000 shares of the business’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now owns 137,488 shares in the company, valued at approximately $10,174,112. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 128,276 shares of company stock worth $9,190,610. Company insiders own 1.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Chicago Partners Investment Group LLC raised its position in Gilead Sciences by 131.8% in the second quarter. Chicago Partners Investment Group LLC now owns 3,312 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 1,883 shares in the last quarter. IFP Advisors Inc raised its position in Gilead Sciences by 18.1% in the second quarter. IFP Advisors Inc now owns 33,487 shares of the biopharmaceutical company’s stock valued at $2,370,000 after buying an additional 5,144 shares in the last quarter. JLB & Associates Inc. bought a new position in Gilead Sciences during the second quarter valued at about $8,068,000. Callahan Advisors LLC raised its position in Gilead Sciences by 4.7% in the second quarter. Callahan Advisors LLC now owns 82,759 shares of the biopharmaceutical company’s stock valued at $5,858,000 after buying an additional 3,731 shares in the last quarter. Finally, Rand Wealth LLC raised its position in Gilead Sciences by 0.7% in the second quarter. Rand Wealth LLC now owns 20,418 shares of the biopharmaceutical company’s stock valued at $1,445,000 after buying an additional 137 shares in the last quarter. 73.99% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.